Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06097728 · ClinicalTrials.gov registry record · Phase 3

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

A Phase 3 study of Unresectable Pleural Mesothelioma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
825
Enrollment target
20
Study locations

NCT06097728 is a Phase 3 study of Unresectable Pleural Mesothelioma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 825 participants. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06097728, a Phase 3 study of Unresectable Pleural Mesothelioma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
825 participants
Enrollment target
20
Study locations

Study Summary

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Conditions Studied

Unresectable Pleural Mesothelioma

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG Nivolumab
  • DRUG Volrustomig

Study Locations (20)

Ohio

  • Research Site - Cleveland
  • Research Site - Cleveland
  • Research Site - Cleveland
  • Research Site - Columbus
  • Research Site - Independence

California

  • Research Site - Duarte
  • Research Site - Santa Rosa

New York

  • Research Site - Commack
  • Research Site - Valhalla

Oregon

  • Research Site - Portland
  • Research Site - Portland

Arizona

  • Research Site - Phoenix

Colorado

  • Research Site - Aurora

Florida

  • Research Site - Jacksonville

Georgia

  • Research Site - Atlanta

Trial Details

FieldValue
Enrollment Target 825 participants
Start Date 2023-11-09
Est. Completion 2028-11-16
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06097728

The ClinicalTrials.gov registry entry for NCT06097728 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 825 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Unresectable Pleural Mesothelioma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT06097728 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Ohio, California, New York.

Frequently Asked Questions

What is clinical trial NCT06097728 about?

NCT06097728 is a clinical study titled "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma". This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

What is the current status of trial NCT06097728?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2023-11-09. Estimated completion is 2028-11-16.

What conditions does trial NCT06097728 study?

This clinical trial studies the following conditions: Unresectable Pleural Mesothelioma.

What interventions are being tested in trial NCT06097728?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Nivolumab (DRUG), Volrustomig (DRUG).

Who is sponsoring clinical trial NCT06097728?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06097728 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Explore more on PlainTrial

Unresectable Pleural Mesothelioma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.